MiNK Therapeutics Inc

NEW
NAS:INKT (USA)  
$ 9.01 -0.030 (-0.33%) 01:39 PM EST
At Loss
Market Cap:
$ 35.74M
Enterprise V:
$ 36.20M
Volume:
3.06K
Avg Vol (2M):
40.44K
Trade In:
What is a stock summary page? Click here for an overview.
Volume:
3.06K
At Loss
Avg Vol (2M):
40.44K

Business Description

Description
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
Name Current Vs Industry Vs History
Cash-To-Debt 0.93
Equity-to-Asset -3.42
Debt-to-Equity -0.25
Debt-to-EBITDA -0.47
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate 27
3-Year EPS without NRI Growth Rate 30.4
3-Year FCF Growth Rate 20.4

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.72
Quick Ratio 0.72
Cash Ratio 0.66

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -5.8
Shareholder Yield % -16.92
Name Current Vs Industry Vs History
ROA % -154.66
ROIC % -330.92
3-Year ROIIC % -242.78
ROC (Joel Greenblatt) % -1258.39

GF Value Rank

Name Current Vs Industry Vs History
EV-to-EBIT -3.4
EV-to-Forward-EBIT -2.92
EV-to-EBITDA -3.47
EV-to-FCF -3.52
Earnings Yield (Greenblatt) % -29.41
FCF Yield % -26.74

Financials (Next Earnings Date:2025-05-14 Est.)

INKT's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:INKT

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016

MiNK Therapeutics Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -2.96
Beta 0.15
3-Year Sharpe Ratio -0.3
3-Year Sortino Ratio -0.57
Volatility % 38.87
14-Day RSI 54.11
14-Day ATR ($) 1.031246
20-Day SMA ($) 8.55628
12-1 Month Momentum % 13.48
52-Week Range ($) 4.5601 - 19
Shares Outstanding (Mil) 3.96

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

MiNK Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

MiNK Therapeutics Inc Stock Events

Financials Calendars
Event Date Price ($)
No Event Data

MiNK Therapeutics Inc Frequently Asked Questions

What is MiNK Therapeutics Inc(INKT)'s stock price today?
The current price of INKT is $9.01. The 52 week high of INKT is $19.00 and 52 week low is $4.56.
When is next earnings date of MiNK Therapeutics Inc(INKT)?
The next earnings date of MiNK Therapeutics Inc(INKT) is 2025-05-14 Est..
Does MiNK Therapeutics Inc(INKT) pay dividends? If so, how much?
MiNK Therapeutics Inc(INKT) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1